Kazuya Shimoda, Norio Komatsu, Itaru Matsumura, Kazuhiko Ikeda, Masayuki Hino, Michihiro Hidaka, Yoshinobu Maeda, Takeshi Kondo, Tomoaki Fujisaki, Keita Shoshi, et al. Momelotinib versus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: an efficacy/safety analysis in the Japanese subgroup of the phase 3 randomized SIMPLIFY-1 trial. International journal of hematology. 2024
Keiki Nagaharu, Eiko Ohya, Yoko Edahiro, Yoshinori Hashimoto, Tomoki Ito, Akihiko Gotoh, Mika Nakamae, Fumihiko Kimura, Michiaki Koike, Keita Kirito, et al. Predictive significance of high neutrophil ratio for thrombosis in myeloproliferative neoplasms: JSH-MPN-R18 subanalysis. Annals of hematology. 2024
Yuji Nozaki, Hisaya Akiba, Hiroki Akazawa, Hirotaka Yamazawa, Kaori Ishimura, Koji Kinoshita, Itaru Matsumura. Inhibition of the TIM-1 and -3 Signaling Pathway Ameliorates Disease in a Murine Model of Rheumatoid Arthritis. Clinical and experimental immunology. 2024
Itaru Matsumura, Shigeki Ohtake, Yoshiko Atsuta, Mio Kurata, Yosuke Minami, Naoto Takahashi, Chiaki Nakaseko, Noriyoshi Iriyama, Katsumichi Fujimaki, Kazuhiko Kakihana, et al. Nilotinib vs. Dasatinib in Achieving MR4.5 for de novo Chronic Myeloid Leukemia: the Randomized JALSG CML212 Study. Blood advances. 2024
Yosuke Minami, Noriko Doki, Hiroshi Matsuoka, Takafumi Yokota, Akihiro Tomita, Naoto Takahashi, Kohmei Kubo, Tatsunori Goto, Keita Kirito, Akio Maki, et al. Asciminib in Patients With CML-CP Previously Treated With ≥ 2 Tyrosine Kinase Inhibitors: 96-Week Results From the Japanese Subgroup Analysis of the ASCEMBL Study. International journal of hematology. 2024